Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use Surveillance of Adcetris in CD30-positive PTCL and Hodgkin lymphoma (Japan)
jRCT1080224999Completed
- Sponsor
- Takeda
- Start
- Dec 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brentuximab vedotin in peripheral T-cell lymphoma (PTCL) and Hodgkin lymphoma (HL), sponsored by Takeda. Started Dec 2019; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
peripheral T-cell lymphoma (PTCL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on jRCT1080224999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080224999.